Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | BAKER BROS. ADVISORS LP | 10,204,089 4.980% | -8,980,705 (-46.81%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | BAKER BROS. ADVISORS LP | 269,213 9.990% | 88,300 (+48.81%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Biomea Fusion, Inc. BMEA | BAKER BROS. ADVISORS LP | 2,108,949 5.900% | 4,390 (+0.21%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Athira Pharma, Inc. ATHA | BAKER BROS. ADVISORS LP | 3,153,807 8.300% | 3,153,807 (New Position) | Filing History |
| 2024-02-12 4:10 pm Purchase | 2024-01-31 | 13G | Bicycle Therapeutics plc BCYC | BAKER BROS. ADVISORS LP | 4,823,598 12.800% | 4,823,598 (New Position) | Filing History |
| 2024-02-01 5:25 pm Sale | 2024-01-30 | 13D | Immunocore Holdings plc IMCR | BAKER BROS. ADVISORS LP | 2,452,871 4.990% | -2,232,819 (-47.65%) | Filing History |
| 2024-01-10 4:58 pm Purchase | 2023-12-31 | 13G | Sera Prognostics, Inc. SERA | BAKER BROS. ADVISORS LP | 5,434,399 17.900% | 5,434,399 (New Position) | Filing History |
| 2024-01-10 4:57 pm Purchase | 2023-12-31 | 13G | Replimune Group, Inc. REPL | BAKER BROS. ADVISORS LP | 9,545,336 16.200% | 3,777,109 (+65.48%) | Filing History |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 5,995,928 10.800% | 3,116,103 (+108.20%) | Filing History |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Atreca, Inc. BCEL | BAKER BROS. ADVISORS LP | 7,677,982 19.990% | 4,145,222 (+117.34%) | Filing History |
| 2023-12-20 5:24 pm Purchase | 2023-12-18 | 13D | Neurogene Inc. NGNE | BAKER BROS. ADVISORS LP | 649,685 4.990% | 649,685 (New Position) | Filing History |
| 2023-12-18 5:25 pm Sale | 2023-12-14 | 13D | Seagen Inc. SGEN | BAKER BROS. ADVISORS LP | 0 0.000% | -45,074,469 (Position Closed) | Filing History |
| 2023-12-15 5:20 pm Purchase | 2023-12-15 | 13D | IGM Biosciences, Inc. IGMS | BAKER BROS. ADVISORS LP | 3,744,669 11.400% | 467,102 (+14.25%) | Filing History |
| 2023-12-13 4:55 pm Purchase | 2023-12-11 | 13D | Prelude Therapeutics Incorporated PRLD | BAKER BROS. ADVISORS LP | 10,222,968 24.300% | 3,888 (+0.04%) | Filing History |
| 2023-11-24 1:43 pm Purchase | 2023-11-21 | 13D | Bellicum Pharmaceuticals, Inc. BLCM | BAKER BROS. ADVISORS LP | 2,365,472 19.990% | 167,553 (+7.62%) | Filing History |
| 2023-11-21 5:24 pm Sale | 2023-11-17 | 13D | Madrigal Pharmaceuticals, Inc. MDGL | BAKER BROS. ADVISORS LP | 1,987,702 9.990% | -28,058 (-1.39%) | Filing History |
| 2023-11-14 5:18 pm Sale | 2023-11-14 | 13D | BeiGene, Ltd. ONC | BAKER BROS. ADVISORS LP | 138,678,037 13.000% | -14,300,000 (-9.35%) | Filing History |
| 2023-11-13 4:22 pm Purchase | 2023-10-31 | 13G | Cerus Corporation CERS | BAKER BROS. ADVISORS LP | 19,101,876 10.500% | 3,014,454 (+18.74%) | Filing History |
| 2023-10-10 4:42 pm Purchase | 2023-10-05 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS. ADVISORS LP | 473,667 19.990% | 473,667 (New Position) | Filing History |
| 2023-10-05 4:36 pm Purchase | 2023-10-03 | 13D | Madrigal Pharmaceuticals, Inc. MDGL | BAKER BROS. ADVISORS LP | 2,015,760 9.990% | 470,647 (+30.46%) | Filing History |